Evidence map›Paper›PMID 22090118›Full record

ArticleJournal of virology2012

Cooperation between viral interferon regulatory factor 4 and RTA to activate a subset of Kaposi's sarcoma-associated herpesvirus lytic promoters.

Xiangmei Xi, Linda M Persson, Michael W O'Brien, Ian Mohr, Angus C Wilson

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Kaposi sarcoma herpesvirus pathogenesis.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2017
    Review
  9. Article
  10. Multicentric Castleman disease: Where are we now?Seminars in diagnostic pathology · 2016
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Xiangmei XiDepartment of Microbiology and NYU Cancer Institute, New York University School of Medicine, New York, New York, USA.
Linda M Persson
Michael W O'Brien
Ian Mohr
Angus C Wilson
New York University · US

Funding

VIROLOGY COREP30AI027742 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GORNY, MIROSLAW K · 1989 to 2010
$19.4M
Control of Translation in Herpesvirus Infected Cells - Resubmission - 1R01GM056927 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Ian J Mohr · 1999 to 2026
$7.6M
Virus Host Interactions that Regulate Translation in Cells Infected with HSV-1R01AI073898 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MOHR, IAN J · 2008 to 2020
$5.0M
REGULATION OF HSV GENE EXPRESSION BY HCFR01GM061139 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WILSON, ANGUS C · 2001 to 2009
$2.6M
LEICA TCS SP2 ADBS CONFOCAL MICROSCOPES10RR017970 · NCRR · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BOROWIEC, JAMES A. · 2003 to 2003
$361k
NCRR NIH HHS S10RR017970NIAID NIH HHS P30 AI027742NIAID NIH HHS R01 AI073898NIGMS NIH HHS GM61139NIGMS NIH HHS R01 GM056927NIGMS NIH HHS R01 GM061139
6 · The paper itself

Abstract

The four Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded interferon (IFN) regulatory factor homologues (vIRF1 to vIRF4) are used to counter innate immune defenses and suppress p53. The vIRF genes are arranged in tandem but differ in function and expression. In KSHV-infected effusion lymphoma lines, K10.5/vIRF3 and K11/vIRF2 mRNAs are readily detected during latency, whereas K9/vIRF1 and K10/vIRF4 mRNAs are upregulated during reactivation. Here we show that the K10/vIRF4 promoter responds to the lytic switch protein RTA in KSHV-infected cells but is essentially unresponsive in uninfected cells. Coexpression of RTA with vIRF4 is sufficient to restore regulation, a property not shared by other vIRFs. The K9/vIRF1 promoter behaves similarly, and production of infectious virus is enhanced by the presence of vIRF4. Synergy requires the DNA-binding domain (DBD) and C-terminal IRF homology regions of vIRF4. Mutations of arginine residues within the putative DNA recognition helix of vIRF4 or the invariant cysteines of the adjacent CxxC motif abolish cooperation with RTA, in the latter case by preventing self-association. The oligomerization and transactivation functions of RTA are also essential for synergy. The K10/vIRF4 promoter contains two transcription start sites (TSSs), and a 105-bp fragment containing the proximal promoter is responsive to vIRF4/RTA. Binding of a cellular factor(s) to this fragment is altered when both viral proteins are present, suggesting a possible mechanism for transcriptional synergy. Reliance on coregulators encoded by either the host or viral genome provides an elegant strategy for expanding the regulatory potential of a master regulator, such as RTA.

Indexed as

Gene Expression Regulation, ViralPromoter Regions, GeneticAmino Acid MotifsBase SequenceBinding SitesCell Line, TumorHerpesviridae InfectionsHerpesvirus 8, HumanHumansImmediate-Early ProteinsInterferon Regulatory FactorsMolecular Sequence DataProtein BindingTrans-ActivatorsTranscriptional ActivationViral ProteinsImmediate-Early ProteinsInterferon Regulatory FactorsRta protein, Human herpesvirus 8Trans-Activatorsviral interferon regulatory factorsViral Proteins

Identifiers

PMID22090118
PMCPMC3255833
OpenAlexW2030171702

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.